China’s National Medical Products Administration approved two new differentiated therapies aimed at lowering acute and seasonal disease burdens. Everest Medicines’ Cardamyst received clearance as a self-administered nasal spray for paroxysmal supraventricular tachycardia, while Simcere Pharmaceutical’s Yingmule was approved as a long-acting monoclonal antibody to prevent RSV-related lower respiratory tract infections in newborns and infants. Both approvals highlight a mix of home-use cardiovascular innovation and seasonal passive immunization designed to reduce severe respiratory outcomes. For Everest, Cardamyst becomes the company’s first innovative cardiovascular product in China; for Simcere, Yingmule expands its anti-infective portfolio and supports its commercialization structure. The authorizations also reflect ongoing regulatory prioritization of at-home delivery formats and preventive immunotherapies in pediatrics, where clinical benefit can be tightly linked to reduced hospitalization risk.